We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33. Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with...
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue...
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and...
Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.2493 | 28.988372093 | 0.86 | 1.35 | 0.82 | 2273328 | 1.22421261 | CS |
4 | 0.2293 | 26.0568181818 | 0.88 | 1.35 | 0.8 | 964356 | 1.09629538 | CS |
12 | 0.3993 | 56.2394366197 | 0.71 | 1.35 | 0.6354 | 643684 | 0.94902037 | CS |
26 | 0.0793 | 7.69902912621 | 1.03 | 1.35 | 0.6354 | 712482 | 0.91842073 | CS |
52 | -1.1407 | -50.6977777778 | 2.25 | 3.1399 | 0.6354 | 521769 | 1.1845799 | CS |
156 | -10.7007 | -90.6071126164 | 11.81 | 12.73 | 0.6354 | 264210 | 2.42592091 | CS |
260 | -40.9107 | -97.3600666349 | 42.02 | 63.62 | 0.6354 | 241417 | 6.25302185 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions